Margalioth E J, Udassin R, Maor J, Schenker J G
Cancer. 1985 Aug 15;56(4):856-9. doi: 10.1002/1097-0142(19850815)56:4<856::aid-cncr2820560425>3.0.co;2-q.
Serum copper levels (SCL) were determined before any diagnostic procedure was performed or treatment given in 40 women admitted for the investigation of a pelvic mass and, later, in those patients with ovarian carcinoma after chemotherapy and before a second-look operation was performed. Patients with ovarian carcinoma were found to have significantly higher SCL than patients with benign ovarian lesions. A SCL of 150 micrograms/dl clearly separated patients with a pelvic mass on the basis of ovarian carcinoma and those with benign noninflammatory pelvic lesions. The same SCL of 150 micrograms/dl separated patients with ovarian carcinoma that responded to chemotherapy and those with residual disease. It is suggested that SCL be included as a member of the screening panel of biologic tumor markers in general and in ovarian carcinoma in particular.
在对40名因盆腔肿块入院检查的女性进行任何诊断程序或给予治疗之前，测定了她们的血清铜水平（SCL），随后在这些卵巢癌患者化疗后及进行二次探查手术前也进行了测定。发现卵巢癌患者的SCL显著高于良性卵巢病变患者。血清铜水平为150微克/分升时，能明显区分出患有卵巢癌盆腔肿块的患者和患有良性非炎性盆腔病变的患者。同样是150微克/分升的血清铜水平，能区分出对化疗有反应的卵巢癌患者和有残留病灶的患者。建议将血清铜水平一般作为生物肿瘤标志物筛查指标之一，尤其是在卵巢癌筛查中。
